• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

柔红霉素与DNA相互作用的位点及序列特异性

Site and sequence specificity of the daunomycin-DNA interaction.

作者信息

Chaires J B, Fox K R, Herrera J E, Britt M, Waring M J

机构信息

Department of Biochemistry, University of Mississippi Medical Center, Jackson 39216-4505.

出版信息

Biochemistry. 1987 Dec 15;26(25):8227-36. doi: 10.1021/bi00399a031.

DOI:10.1021/bi00399a031
PMID:2831939
Abstract

The site and sequence specificity of the daunomycin-DNA interaction was examined by equilibrium binding methods, by deoxyribonuclease I footprinting studies, and by examination of the effect of the antibiotic on the cleavage of linearized pBR322 DNA by restriction endonucleases PvuI and EcoRI. These three experimental approaches provide mutually consistent results showing that daunomycin indeed recognizes specific sites along the DNA lattice. The affinity of daunomycin toward natural DNA increases with increasing GC content. The quantitative results are most readily explained by binding models in which daunomycin interacts with sites containing two adjacent GC base pairs, possibly occurring as part of a triplet recognition sequence. Deoxyribonuclease I footprinting studies utilizing the 160 base pair (bp) tyrT DNA fragment and 61 and 53 bp restriction fragments isolated from pBR322 DNA further define the sequence specificity of daunomycin binding. Specific, reproducible protection patterns were obtained for each DNA fragment at 4 degrees C. Seven protected sequences, ranging in size from 4 to 14 bp, were identified within the tyrT fragment. Relative to the overall tyrT sequence, these protected sequences were GC rich and contained a more limited and distinct distribution of di- and trinucleotides. Within all of the protected sequences, a triplet containing adjacent GC base pairs flanked by an AT base pair could be found in one or more copies. Nowhere in the tyrT fragment did that triplet occur outside a protected sequence. The same triplet occurred within seven out of nine protected sequences observed in the fragments isolated from pBR322 DNA. In the two remaining cases, three contiguous GC base pairs were found. We conclude that the preferred daunomycin triplet binding site contains adjacent GC base pairs, of variable sequence, flanked by an AT base pair. This conclusion is consistent with the results of a recent theoretical study of daunomycin sequence specificity [Chen, K.-X., Gresh, N., & Pullman, B. (1985) J. Biomol. Struct. Dyn. 3, 445-466]. Adriamycin and the beta-anomer of adriamycin produce the same qualitative pattern of protection as daunomycin with the tyrT fragment. Daunomycin inhibits the rate of digestion of pBR322 DNA by PvuI (recognition sequence 5'-CGATCG-3') to a greater extent than it does EcoRI (recognition sequence 5'-GAATTC-3'), a finding consistent with the conclusions derived from our footprinting studies. Our results, as a whole, are the clearest indication to date that daunomycin recognizes a specific DNA sequence as a preferred binding site.

摘要

通过平衡结合方法、脱氧核糖核酸酶I足迹研究以及考察该抗生素对限制性内切酶PvuI和EcoRI切割线性化pBR322 DNA的影响,研究了柔红霉素与DNA相互作用的位点和序列特异性。这三种实验方法提供了相互一致的结果,表明柔红霉素确实能识别DNA晶格上的特定位点。柔红霉素对天然DNA的亲和力随GC含量的增加而增强。定量结果最容易用结合模型来解释,即柔红霉素与含有两个相邻GC碱基对的位点相互作用,这些位点可能作为三联体识别序列的一部分出现。利用160个碱基对(bp)的tyrT DNA片段以及从pBR322 DNA中分离出的61和53 bp的限制性片段进行的脱氧核糖核酸酶I足迹研究,进一步明确了柔红霉素结合的序列特异性。在4℃下,每个DNA片段都获得了特异的、可重复的保护模式。在tyrT片段中鉴定出7个受保护序列,大小从4到14 bp不等。相对于整个tyrT序列,这些受保护序列富含GC,并且二核苷酸和三核苷酸的分布更有限且独特。在所有受保护序列中,都能找到一个或多个包含由AT碱基对侧翼的相邻GC碱基对的三联体。在tyrT片段中,该三联体从未出现在受保护序列之外的地方。在从pBR322 DNA分离出的片段中观察到的9个受保护序列中,有7个包含相同的三联体。在另外两个案例中,发现了三个相邻的GC碱基对。我们得出结论,柔红霉素的优选三联体结合位点包含由AT碱基对侧翼的可变序列的相邻GC碱基对。这一结论与最近关于柔红霉素序列特异性的理论研究结果一致[Chen, K.-X., Gresh, N., & Pullman, B. (1985) J. Biomol. Struct. Dyn. 3, 445 - 466]。阿霉素及其β-端基异构体与tyrT片段产生与柔红霉素相同的定性保护模式。柔红霉素对PvuI(识别序列5'-CGATCG-3')切割pBR322 DNA的速率的抑制作用比对EcoRI(识别序列5'-GAATTC-3')的抑制作用更大,这一发现与我们足迹研究得出的结论一致。总体而言,我们的结果是迄今为止最明确的迹象,表明柔红霉素将特定的DNA序列识别为优选的结合位点。

相似文献

1
Site and sequence specificity of the daunomycin-DNA interaction.柔红霉素与DNA相互作用的位点及序列特异性
Biochemistry. 1987 Dec 15;26(25):8227-36. doi: 10.1021/bi00399a031.
2
Preferential binding of daunomycin to 5'ATCG and 5'ATGC sequences revealed by footprinting titration experiments.
Biochemistry. 1990 Jul 3;29(26):6145-53. doi: 10.1021/bi00478a006.
3
Elucidation of the DNA sequence preferences of daunomycin.阐明柔红霉素的DNA序列偏好性。
Drug Des Deliv. 1988 Jul;3(2):125-51.
4
Binding of daunomycin to diaminopurine- and/or inosine-substituted DNA.柔红霉素与二氨基嘌呤和/或肌苷取代的DNA的结合。
Biochemistry. 1998 Jan 27;37(4):1033-45. doi: 10.1021/bi9716128.
5
Association of anthracyclines and synthetic hexanucleotides. Structural factors influencing sequence specificity.
J Mol Recognit. 1989 Nov;2(3):132-41. doi: 10.1002/jmr.300020306.
6
Avian retrovirus pp32 DNA-binding protein. I. Recognition of specific sequences on retrovirus DNA terminal repeats.禽逆转录病毒pp32 DNA结合蛋白。I. 对逆转录病毒DNA末端重复序列上特定序列的识别。
J Virol. 1982 Oct;44(1):330-43. doi: 10.1128/JVI.44.1.330-343.1982.
7
The 5'-CA DNA-sequence preference of daunomycin.柔红霉素对5'-CA DNA序列的偏好性。
FEBS Lett. 1988 Jan 25;227(2):103-6. doi: 10.1016/0014-5793(88)80877-9.
8
Nucleotide sequence binding preferences of nogalamycin investigated by DNase I footprinting.通过DNA酶I足迹法研究诺加霉素的核苷酸序列结合偏好性。
Biochemistry. 1986 Jul 29;25(15):4349-56. doi: 10.1021/bi00363a026.
9
Enzymatic and chemical footprinting of anthracycline antitumor antibiotics and related saccharide side chains.蒽环类抗肿瘤抗生素及相关糖侧链的酶促和化学足迹分析。
Biochemistry. 1996 Jun 18;35(24):7974-82. doi: 10.1021/bi952495o.
10
Involvement of outside DNA sequences in the major kinetic path by which EcoRI endonuclease locates and leaves its recognition sequence.外部DNA序列参与了EcoRI核酸内切酶定位并离开其识别序列的主要动力学途径。
Proc Natl Acad Sci U S A. 1982 Jul;79(13):4010-4. doi: 10.1073/pnas.79.13.4010.

引用本文的文献

1
Isolation, Characterization, and Anticancer Evaluation of Alkaloids from (Rubiaceae).茜草科植物生物碱的分离、表征及抗癌评估
ACS Omega. 2025 Aug 4;10(32):35719-35737. doi: 10.1021/acsomega.5c02401. eCollection 2025 Aug 19.
2
Pilot-Scale Screening of Clinically Approved Drugs to Identify Uridine Insertion/Deletion RNA Editing Inhibitors in .在. 中进行临床批准药物的小规模筛选,以鉴定尿苷插入/缺失 RNA 编辑抑制剂
ACS Infect Dis. 2024 Sep 13;10(9):3289-3303. doi: 10.1021/acsinfecdis.4c00394. Epub 2024 Aug 9.
3
Interactions of a Novel Anthracycline with Oligonucleotide DNA and Cyclodextrins in an Aqueous Environment.
新型蒽环类药物在水相环境中与寡核苷酸 DNA 和环糊精的相互作用。
J Phys Chem B. 2024 Jul 4;128(26):6291-6307. doi: 10.1021/acs.jpcb.4c02213. Epub 2024 Jun 20.
4
DOX-DNA Interactions on the Nanoscale: In Situ Studies Using Tip-Enhanced Raman Scattering.纳米尺度上的 DOX-DNA 相互作用:使用尖端增强拉曼散射的原位研究。
Anal Chem. 2024 Jun 4;96(22):8905-8913. doi: 10.1021/acs.analchem.3c05372. Epub 2024 May 21.
5
pH-Dependent Non-Covalent Release of Chemotherapy from Carriers.载体中化疗药物的 pH 依赖性非共价释放。
Discov Med. 2024 Mar;36(182):448-456. doi: 10.24976/Discov.Med.202436182.42.
6
Sequence specificity in DNA-drug intercalation: MD simulation and density functional theory approaches.DNA 药物嵌入的序列特异性:MD 模拟和密度泛函理论方法。
J Comput Aided Mol Des. 2020 Jan;34(1):83-95. doi: 10.1007/s10822-019-00268-y. Epub 2019 Dec 9.
7
Enhanced tumor uptake and activity of nanoplex-loaded doxorubicin.载药纳米复合物增强了阿霉素的肿瘤摄取和活性。
Biochem Biophys Res Commun. 2019 May 21;513(1):242-247. doi: 10.1016/j.bbrc.2019.03.190. Epub 2019 Apr 4.
8
Advances in delivery systems for doxorubicin.阿霉素递送系统的进展
J Nanomed Nanotechnol. 2018;9(5). doi: 10.4172/2157-7439.1000519. Epub 2018 Nov 4.
9
Discriminating Intercalative Effects of Threading Intercalator Nogalamycin, from Classical Intercalator Daunomycin, Using Single Molecule Atomic Force Spectroscopy.使用单分子原子力光谱法区分插入剂诺加霉素与经典插入剂柔红霉素的插入作用。
PLoS One. 2016 May 16;11(5):e0154666. doi: 10.1371/journal.pone.0154666. eCollection 2016.
10
The development of new anticancer drugs.
World J Microbiol Biotechnol. 1992 Dec;8 Suppl 1:74-6. doi: 10.1007/BF02421499.